These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7157005)

  • 1. Lithium in the prophylactic treatment of recurrent affective disorders.
    Kua EH; Lee SL; Chee KT
    Singapore Med J; 1982 Oct; 23(5):262-4. PubMed ID: 7157005
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbamazepine as adjunct or alternative to lithium in the prophylaxis of recurrent affective disorders.
    Fritze J; Beneke M; Lanczik M; Schneider B; Walden J
    Pharmacopsychiatry; 1994 Sep; 27(5):181-5. PubMed ID: 7838887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
    Dardennes R; Lafuma A; Watkins S
    Encephale; 1999; 25(5):391-400. PubMed ID: 10598301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic lithium treatment: treatment response, and patient attitudes toward illness and treatment.
    Schmidt S; Ludwig W; Seibold S; Greil W
    Pharmacopsychiatry; 1988 Nov; 21(6):274-5. PubMed ID: 3244750
    [No Abstract]   [Full Text] [Related]  

  • 5. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study.
    Juckel G; Mavrogiorgou P; Bredemeier S; Gallinat J; Frodl T; Schulz C; Möller HJ; Hegerl U
    Pharmacopsychiatry; 2004 Mar; 37(2):46-51. PubMed ID: 15048610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced plasma cyclic AMP level during prophylactic lithium treatment in patients with affective disorders.
    Arató M; Rihmer Z; Felszeghy K
    Biol Psychiatry; 1980 Apr; 15(2):319-22. PubMed ID: 6251928
    [No Abstract]   [Full Text] [Related]  

  • 7. Who responds to prophylactic lithium therapy?
    Abou-Saleh MT
    Br J Psychiatry Suppl; 1993 Sep; (21):20-6. PubMed ID: 8217063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effectiveness of lithium in the prophylaxis of affective disorders].
    Ezquiaga E; García-López A; Nieves P; Rodríguez-Salvanés F
    Actas Esp Psiquiatr; 2000; 28(3):156-60. PubMed ID: 11000697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between prophylactic effect of lithium therapy and family history of affective disorders.
    Engström C; Aström M; Nordqvist-Karlsson B; Adolfsson R; Nylander PO
    Biol Psychiatry; 1997 Sep; 42(6):425-33. PubMed ID: 9285078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Follow-up evaluation of the prophylactic effect of lithium carbonate in cyclothymia].
    Strzelecka I
    Psychiatr Pol; 1980; 14(4):421-2. PubMed ID: 7003633
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prophylactic long-term therapy of affective disorders with lithium, valproic acid and carbamazepine--effectiveness and cost-effectiveness].
    Roick C; Ahrens B; Becker T
    Psychiatr Prax; 2001 Jul; 28 Suppl 1():S32-40. PubMed ID: 11533905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Lithium and other preventive agents of affective disorders in 1983].
    Soucek K; Zvolský P
    Cesk Psychiatr; 1984 Aug; 80(4):247-51. PubMed ID: 6499034
    [No Abstract]   [Full Text] [Related]  

  • 13. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.
    Serretti A; Malitas PN; Mandelli L; Lorenzi C; Ploia C; Alevizos B; Nikolaou C; Boufidou F; Christodoulou GN; Smeraldi E
    Pharmacogenomics J; 2004; 4(4):267-73. PubMed ID: 15111989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mood disorders: pharmacologic prevention of recurrences. A National Institutes of Health consensus report synopsis.
    Hull RH
    Indiana Med; 1985 Jan; 78(1):36-7. PubMed ID: 3968418
    [No Abstract]   [Full Text] [Related]  

  • 15. The challenge of predicting response to stabilising lithium treatment. The importance of patient selection.
    Grof P; Alda M; Grof E; Fox D; Cameron P
    Br J Psychiatry Suppl; 1993 Sep; (21):16-9. PubMed ID: 8217062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological factors in affective disorders and their relevance to lithium prophylaxis.
    Mendlewicz J
    Pharmacopsychiatria; 1982 Jan; 15(1):11-8. PubMed ID: 7063525
    [No Abstract]   [Full Text] [Related]  

  • 17. Consensus development summaries. Mood disorders: pharmacologic prevention of recurrences. National Institutes of Health.
    Conn Med; 1985 Mar; 49(3):157-63. PubMed ID: 3987266
    [No Abstract]   [Full Text] [Related]  

  • 18. Possible relationship between outcome in primary affective disorders treated with lithium and family history.
    Morabito A; Gasperini M; Macciardi F; Smeraldi E
    Adv Biochem Psychopharmacol; 1982; 32():157-63. PubMed ID: 7090891
    [No Abstract]   [Full Text] [Related]  

  • 19. Affective disorders & "chemical dependence": lithium for alcohol and drug addiction? A clinical note.
    Flemenbaum A
    Dis Nerv Syst; 1974 Jun; 35(6):281-5. PubMed ID: 17894301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mood disorders.
    Am Fam Physician; 1984 Dec; 30(6):99, 102. PubMed ID: 6507233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.